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the study compared results across three types of health
plans, namely, indemnity, HMO, and PPO.
METHODS: A survey instrument was administered to
2,000 patients randomly identified from a pharmacy
claims database. The survey instrument included the SF-12
scale and questions measuring patient satisfaction with
pharmacy benefit services. Patient satisfaction was mea-
sured using a seven-point, eight-item scale, where 7 = ex-
tremely satisfied and 1 = extremely dissatisfied. Demo-
graphic variables such as age, gender, SSRI drug taken,
and type of health plan were obtained from the claims
database.
RESULTS: Preliminary data of 327 completed surveys
were coded and analyzed using statistical tests. A multi-
variate analysis of variance test indicated no significant
effect of SSRI drug taken or the type of health plan en-
rolled on variables measured (p > 0.05). There was also
no significant association between scores of the SF-12
scale (both the physical and mental component) and pa-
tient satisfaction with pharmacy benefits. In general, pa-
tients were very satisfied (5.83 :±: 0.74) with the phar-
macy/prescription benefits, and they indicated their
health status to be very good (3.45 :±: 0.92). The physical
and mental component of the SF-12 scores were compa-
rable to those of the national average, 52.68 :±: 11.99 and
52.38 :±: 18.66, respectively.
CONCLUSIONS: The results of this study indicate that
consumers are very satisfied with the services offered by
the pharmacy/prescription benefit.
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OBJECTIVE: The purpose of this ongoing prospective
study was to document the quality of life and adverse re-
actions reported by ambulatory patients receiving phar-
maceutical care from the Community Pharmacist Re-
search Network.
METHODS: Pharmacists collected demographic and pre-
scription data, and verified that each patient was treated
for depression for at least three months and received no
other medications. Patients completed the SF-36 ques-
tionnaire and a symptoms checklist.
RESULTS: Thirty-one white patients, 20 females and 11
males, completed study instruments. Twenty-seven pa-
tients were receiving selective serotonin reuptake inhibi-
tors (SSRIs), including fluoxetine (13), paroxetine (8),
and sertraline (6); four patients were receiving non-SSRls.
The mean age of patients receiving SSRls was 45 years,
and patients receiving non-SSRIs was 41 years. Twenty-
three patients received antidepressants prescribed by non-
psychiatrists. Mean transformed scale scores from the SF-36
were calculated for patients receiving SSRls and non-
SSRls, respectively, as: physical functioning 87.59 vs.
79
72.5; role (physical) 83.33 vs. 50; bodily pain 75.88 vs,
68.3; general health 71.29 vs. 47.25; vitality 52.77 vs.
51.25; social functioning 76.92 vs. 71.87; role (emo-
tional) 70.35 vs, 66.6; and mental health 66.96 vs. 59.
Six patients reported the presence of sexual dysfunction;
seven reported nervousness; seven reported diarrhea;
seven reported difficulty falling asleep; eight reported
changes in sexual interests; eight reported blurred vision;
eight reported constipation; nine reported weight gain;
nine reported drowsiness; and sixteen reported dry
mouth.
CONCLUSION: Based upon these real world findings,
similar studies are warranted. Although patients receiving
SSRls experienced clinically significant side effects,
health-related quality of life in all SF-36 domains was
better for these patients compared to patients receiving
non-SSRI drugs. These findings have great relevance for
the care of depressed patients.
PMH5
THE COST OF TREATING SCHIZOPHRENIA IN
THE CALIFORNIA MEDICAID (MEDI-CAL)
PROGRAM
McCombs JS, Nichol MB
Department of Pharmaceutical Economics and Policy, School of
Pharmacy, University of Southem Califomia, Los Angeles,
CA, USA
This study investigated the health care costs for schizo-
phrenic patients while documenting the relationship be-
tween health care costs and the patient's use of antipsy-
chotic medications.
METHODS: Paid claims data from the Medi-Cal pro-
gram were used to identify schizophrenic patients with a
minimum of 1 year of data available for analysis (n =
2,680). Patients were divided into treated and untreated
populations based on their purchase of at least one pre-
scription for an antipsychotic medication during the year.
Drug use patterns for treated patients documented the ex-
tent to which patients delayed drug therapy or switches in
drug therapy occurred during the first year. Multivariate
logistic regression models were estimated to investigate
the factors related to delays in therapy or switching thera-
pies. OLS regression models were used to estimate the
health care costs associated with these drug use patterns.
RESULTS: Direct health care cost per schizophrenic pa-
tients averaged $24,000 per year. Nearly 21 % of schizo-
phrenic patients used no antipsychotic drug therapy for
up to one year, which was not associated with increased
costs. Over 27% of treated patients delayed treatment,
resulting in increased costs of between $3,262 (p < .08)
and $6,189 (p ~ .01). 41 % of treated patients with no
delays in therapy switched therapy within 1 year at a cost
of approximately $8,000 (p < .01). Only 11 % of treated
patients consistently purchased antipsychotic medications
during the first year. However, long term use was not as-
sociated with lower costs. An intent-to-treat analysis
failed to document any differences between medications.
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CONCLUSIONS: Schizophrenia patients consume signif-
icant health care resources. Medications used to treat
schizophrenia did not differ in terms of duration of ther-
apy or impact on total health care costs.
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Hospitals, health care systems, and policy makers are
striving to seek ways to provide cost-effective care for pa-
tients with major depressive disorder.
OBJECTIVES: The first objective is to investigate the dif-
ferences between the newer antidepressants regarding
treatment completion, average daily dose, dosage titration,
switching, and augmentation behavior. The second objec-
tive is to compare direct health service expenditures related
to the treatment of depression. The inquiry is guided by the
following question: Is there a significant difference be-
tween antidepressants in regard to overall health care ser-
vice expenditures for the treatment of depression?
METHODS: Retrospective archival data from computer-
ized claims records of a large managed care organization
were analyzed. Treatment completion was defined as re-
ceiving at least 180 days of therapy at a minimum thera-
peutic dose as defined by the AHCPR guidelines for de-
tection, diagnosis, and treatment of depression. Patients
were included in the analysis if (1) they had an ICD-9 di-
agnosis code for depression or if (2) they received an anti-
depressant prescription. Patients were excluded if (1) they
were less than 18 years of age, (2) they had a diagnosis
indicating schizophrenia or bipolar depression, (3) there
were not at least 6 months of follow up data available, or
(4) they were ineligible for coverage by the plan.
RESULTS: Patients initiated on fluoxetine were more
likely to complete therapy than those on paroxetine, ser-
traline, nefazodone, or venlafaxine (n = 65,792; p <
.01). These differences narrowed over time. Results re-
garding overall health care utilization related to each an-
tidepressant will be presented.
CONCLUSIONS: Based on this sample of patients, it ap-
pears that patients initiated on fluoxetine are more likely
to complete therapy when compared to the other anti-
depressants.
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Abstracts
While sedative-hypnotic agents may be equally effective
in promoting sleep, some may lead to greater impairment
in psychomotor functioning and an increased risk of mo-
tor vehicle accidents (MYAs).
OBJECTIVE: To create a general model of the impact of
alternative sedative-hypnotic agents on the expected num-
bers and associated costs of MYAs.
METHODS: A decision-analytic model was developed to
compare the effects of alternative sedative-hypnotics over
one month in a hypothetical cohort of 100,000 adult
drivers who were not being treated with these agents.
Since insomnia increases the risk of driving drowsy, pos-
sibly leading to additional MYAs, a scenario of no treat-
ment was included for comparison purposes. Outcomes
included the expected numbers of drowsy drivers and
MYAs, and the costs (societal) associated with MYAs.
Model parameters were estimated using published sur-
veys, randomized clinical trials of driving performance,
and epidemiologic studies relating driving impairment to
the risk of MYAs.
RESULTS: If sedative-hypnotics were not used, there
would be 24,300 drowsy drivers (per 100,000 per
month) and 441 MYAs. Monthly accident costs would be
$36 per person. Treatment with a sedative-hypnotic asso-
ciated with limited impairment (e.g., nitrazepam 5 mg
daily) would reduce the number of drowsy drivers to
17,550 but only slightly reduce MYAs (by 2) and
monthly costs (by less than $1 per patient). A medication
that might severely impair driving (e.g., flurazepam 30
mg daily) would not further reduce the number of drowsy
drivers but more than triple MYAs (to 1,488) and
monthly costs (to $122 per person).
CONCLUSIONS: Some sedative-hypnotic agents may
markedly increase the costs of MYAs. Their acquisition
prices alone therefore may provide a poor indication of
overall economic impact.
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Long periods of antipsychotic pharmacotherapy are often
necessary because many of the psychotic conditions indi-
cated for antipsychotics are chronic in nature. Atypical
antipsychotic agents, with a broader response profile and
fewer side effects, may increase the likelihood of achiev-
ing longer periods of pharmacotherapy relative to typical
antipsychotic agents.
OBJECTIVE: This study compares the duration of con-
tinuous therapy between atypical and typical antipsy-
chotics in the naturalistic care setting.
METHODS: Three years of medical claims data from a
large U.S. prescription database were analyzed for 56,682
